The Medical Letter on Drugs and Therapeutics
Dupilumab (Dupixent) for Moderate to Severe Atopic Dermatitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved dupilumab (Dupixent – Sanofi/Regeneron), a subcutaneously-injected fully human monoclonal antibody, for treatment of adults with moderate to severe atopic dermatitis (eczema) that has not responded to topical therapies. It can be used with or without topical corticosteroids.

MECHANISM OF ACTION — Dupilumab binds to the IL-4 receptor alpha subunit shared by interleukin (IL)-4 and IL-13 receptors, inhibiting the signaling of these two cytokines, which are thought to be the drivers of atopic dermatitis, asthma, and possibly other allergic diseases.1

STANDARD TREATMENT — Application of moisturizers, emollients, and barrier creams can reduce the need for pharmacologic treatment of atopic dermatitis. Low-potency topical corticosteroids are generally used for treatment of mild atopic dermatitis that fails ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Dupilumab (Dupixent) for Moderate to Severe Atopic Dermatitis
Article code: 1519b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian